Sun Pharma Advanced Research jumps 11%, extends 2-day rally as US court clears Sezaby PRV
On December 2, 2025, SPARC announced that the U.S. District Court for the District of Columbia granted its motion for summary judgment in the case concerning the issuance of a PRV linked to Sezaby’s approval. The court ruled that the U.S. Food and Drug Administration’s (FDA) decision to withhold the PRV was “contrary to law,” noting that no drug product containing phenobarbital sodium had been “previously approved,” as defined under the relevant statute. The court has provided a 60-day window for an appeal.
Commenting on the decision, SPARC CEO Anil Raghavan said, “We are pleased with the ruling issued today by the U.S. District Court, as it validates SPARC’s long-held position on this matter.”
Sezaby is a benzyl alcohol- and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was approved by the U.S. FDA for the treatment of neonatal seizures, providing a safer option for newborns requiring this critical therapy.
Technical on SPARC: The 14-day Relative Strength Index (RSI) for SPARC is currently at 76.8. Since RSI values above 70 typically indicate that a stock is overbought, this suggests that SPARC may experience a short-term price pullback or correction.
Moving Averages: On the positive side, SPARC is trading above all 8 of its key Simple Moving Averages (SMAs), signalling a strong bullish trend in its short- to medium-term price movement.
Also read: Meesho IPO opens for bidding. Check GMP, price band, review, subscription and other key details
Financial Performance: Despite these technical positives, SPARC has been loss-making for the past 8 consecutive quarters.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
